http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105213401-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_658df3b9d24eb5224b37aaf605741db6 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-425 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-54 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-53 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2009-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cad6d3638361f2328ee2b39b082f8c62 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67e3f1994974c7868491aa3ffbba1bef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de249394b4619980eacc5ff379be8924 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62eebe58b1b558702ea1b5ae33ea13fb |
| publicationDate | 2016-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-105213401-A |
| titleOfInvention | Materials and methods for sensitizing multidrug resistant cells |
| abstract | The invention discloses materials and methods for sensitizing multidrug-resistant cells, and specifically discloses materials and methods for sensitizing multidrug-resistant cancer cells expressing ABCG2 and related protein members of the ATP-binding transporter superfamily. A series of compounds (including (N-(4-chlorophenyl)-2-[(6-{[4,6-bis(4-morpholinyl)-1,3,5-triazin-2-yl ]amino}-1,3-benzothiazol-2-yl)thio]acetamide)) specifically inhibits ABCG2 and can increase the bioavailability of potent anticancer drugs, making certain chemotherapeutic agents useful in the treatment of multidrug Tolerate cancer. It can also be used in combination with chemotherapeutic drugs to treat cancer cells that have not been identified as multidrug resistant. These compounds also exhibit acceleration of the intercellular degradation of ABCG2 and related proteins. It is nontoxic to animals at levels that affect the activity of ABCG2 expressed by multidrug resistant cancer cell lines. |
| priorityDate | 2008-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 46.